Teladoc Health, Inc.
No SEC Form 4 filings for $TDOC in the last 30 days.
Teladoc Health (TDOC) reported Q2 2026 revenue of $606.9 million, down 4% year over year, with BetterHelp revenue $212.6 million, down 11% due to a faster shift from cash pay to insurance. Adjusted EBITDA was $65.7 million. Full-year 2026 guidance: revenue $2.36B to $2.45B and adjusted EBITDA $271M to $303M. CEO Charles Divita said insurance demand outpaced provider capacity.
Levi & Korsinsky said it is investigating Teladoc Health (NYSE: TDOC) after the company reported Q2 2026 revenue of $606.9 million, below consensus of $615 million to $628 million, and cut full-year 2026 revenue guidance to $2.36 billion to $2.45 billion. The notice cites prior guidance changes and comments about BetterHelp cash pay user declines and insurance capacity.
Teladoc (TDOC) shares fell more than 28% after earnings, as the shift toward insurance-covered BetterHelp services is said to be creating a gap between demand and provider capacity. The article cites TDOC’s P/S near 0.48, Q2 cash of about $774M, and expected FY free cash flow of $130M to $170M. Analyst targets range from $5.50 to $11.
Over the past 7 days, alphai's AI scored 7 news stories mentioning TDOC (Teladoc Health, Inc.). Coverage has skewed bearish: 0 bullish, 4 neutral, and 3 bearish.
Recent TDOC coverage spans earnings, market movers and financial news.
Guidance cut tied to BetterHelp cash-pay decline, partially offset by rising insurance revenue run-rate and Integrated Care stability.
Guidance cut and below-consensus Q2 revenue are likely to keep downside pressure on TDOC until investors see stabilization in BetterHelp and cash-pay user trends.
The earnings-driven selloff is framed as a turnaround timing issue tied to BetterHelp economics, not a permanent demand collapse.
Board-level change adds insurance and analytics operating experience, but it is not tied to new financial guidance or a specific near-term catalyst.
Board expansion and committee appointments are typically low-volatility, but can affect governance expectations and near-term sentiment.
alphai scores every news story that mentions TDOC with an AI model for sentiment and relevance, and aggregates insider trades from Teladoc Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Teladoc Health (TDOC) reported Q2 2026 revenue of $606.9 million, down 4% year over year, with BetterHelp revenue $212.6 million, down 11% due to a faster shift from cash pay to insurance. Adjusted EBITDA was $65.7 million. Full-year 2026 guidance: revenue $2.36B to $2.45B and adjusted EBITDA $271M to $303M. CEO Charles Divita said insurance demand outpaced provider capacity.
6 min readLevi & Korsinsky said it is investigating Teladoc Health (NYSE: TDOC) after the company reported Q2 2026 revenue of $606.9 million, below consensus of $615 million to $628 million, and cut full-year 2026 revenue guidance to $2.36 billion to $2.45 billion. The notice cites prior guidance changes and comments about BetterHelp cash pay user declines and insurance capacity.
3 min readTeladoc (TDOC) shares fell more than 28% after earnings, as the shift toward insurance-covered BetterHelp services is said to be creating a gap between demand and provider capacity. The article cites TDOC’s P/S near 0.48, Q2 cash of about $774M, and expected FY free cash flow of $130M to $170M. Analyst targets range from $5.50 to $11.
4 min readTeladoc Health (NYSE:TDOC) said it appointed Mark V. Anquillare, formerly president and COO of Verisk Analytics, to its board. He will sit on the Audit and Compensation committees. Teladoc cited his 30+ years in financial and executive roles, including leading Verisk through its 2009 IPO. Teladoc provides virtual healthcare services.
2 min readTeladoc Health, Inc. (TDOC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. tdoc-20260803 FALSE 0001477449 155 E 44th Street Suite 1700 New York NY 10017 0001477449 2026-08-03 2026-08-03 0001477449 dei:FormerAddressMember 2026-08-03 2026-08-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM
2 min readTeladoc Health (NYSE: TDOC) said it appointed Mark V. Anquillare to its board of directors. He previously served as president and COO of Verisk Analytics and will sit on the Audit and Compensation committees, according to the company. The announcement cites his experience as Verisk CFO and COO and his current board role at Guidewire Software.
2 min readTeladoc Health reported Q2 results with revenue of $606.93M and a net loss of $38.91M, and issued guidance expecting continued losses in Q3 and full-year 2026. The company lowered 2026 revenue guidance to $2.362B-$2.447B and net loss to $181M-$136M, citing pressure from BetterHelp as users shift to insurance-covered care.
6 min readTeladoc Health, owner of BetterHelp, said demand for insurance-covered therapy is outpacing its ability to credential therapists. In Q2, cash-pay therapy revenue fell faster than insurance revenue rose. BetterHelp revenue fell 12% YoY to $213M; insurance revenue was $22M. Shares dropped about 27% after results.
6 min readTeladoc (TDOC) shares fell after the company reported Q2 results that did not meet expectations. The article says analysts remain bullish, with a consensus “Moderate Buy” rating and a mean price target around $8, implying more than 22% upside from the current level.
2 min readTeladoc Health (TDOC) shares fell about 20% in premarket after the company reported Q2 revenue of $606.9 million, down 4% year over year, and guided Q3 revenue to $569 million to $609 million versus a Street view of $629.3 million. Teladoc also forecast a Q3 loss of 30 cents to 20 cents per share.
4 min read
